The success of palbociclib in Phase II trials is a good news for Pfizer Inc. (NYSE:PFE) coming on the heels of the bad news of a U.S. court invalidating Pfizer’s patent for blockbuster drug Celebrex. Pfizer Inc. (NYSE:PFE), shares after opening at $30.99 moved to $31.25 on last trade day and at the end of the day closed at $31.23. Company price to sales ratio in past twelve months was calculated as 3.87 and price to cash ratio as 6.16. Pfizer Inc. (NYSE:PFE), showed a negative weekly performance of 3.28%.
Pressure is mounting from Express Scripts Holding Co. (ESRX) over Gilead Sciences, Inc. (NASDAQ:GILD) to lower down its hepatitis C pill Sovaldi’s price, which is currently priced $84,000. Gilead Sciences, Inc. (NASDAQ:GILD), shares advanced 0.91% in last trading session and ended the day on $70.65. Gilead Sciences, Inc. (NASDAQ:GILD), return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD), yearly performance is 42.07%.
Any breakthrough in the field of medicine, especially, incurable or hard-to-cure diseases generate hype. It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK) called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC). It also is effective in treating advanced melanoma. This drug was presented in the annual meeting of the American Association for Cancer Research. Merck & Co., Inc. (NYSE:MRK), shares moved up 3.74% in last trading session and was closed at $57.10, while trading in range of $ 55.20 – 57.15. Merck & Co., Inc. (NYSE:MRK), year to date (YTD) performance is 14.98%.
The leading healthcare company, Abbott Laboratories (NYSE:ABT), has invariably continued to contribute significantly to the global healthcare. By developing technologies and products that would see a tremendous change in the healthcare sector, this globally famous company has maintained its most crucial stand in improving people’s life worldwide. Abbott Laboratories (NYSE:ABT), weekly performance is -2.46%. On last trading day company shares ended up $37.63. Abbott Laboratories (NYSE:ABT), distance from 50-day simple moving average (SMA50) is 2.20%. Analysts mean target Price for the company is $41.75.
Leave a Reply